Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis
Authors
Keywords
-
Journal
BJS Open
Volume 6, Issue 3, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-02-15
DOI
10.1093/bjsopen/zrac028
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin®) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin)
- (2021) MARCUS SCHMIDT et al. ANTICANCER RESEARCH
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
- (2021) Larissa A. Korde et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer – A retrospective cohort study
- (2021) Matthew G. Davey et al. BREAST
- Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis.
- (2020) Laura M. Spring et al. CLINICAL CANCER RESEARCH
- Prognostic value of residual disease after neoadjuvant therapy in HER2+ breast cancer evaluated by Residual Cancer Burden, Neoadjuvant Response Index & Neo-Bioscore
- (2019) Tessa G Steenbruggen et al. CLINICAL CANCER RESEARCH
- Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy
- (2019) Joanne W Chiu et al. POSTGRADUATE MEDICAL JOURNAL
- Insulin-like growth factor-1, metabolic abnormalities, and pathological complete remission rate in HER2-positive breast cancer patients receiving neoadjuvant therapy
- (2019) Yi-wei Tong et al. OncoTargets and Therapy
- Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
- (2019) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
- (2019) Helena M Earl et al. LANCET
- Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
- (2019) Sandra M. Swain et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab
- (2019) Noriko Fujita et al. ONCOLOGY
- Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy
- (2018) Waqar Haque et al. BREAST CANCER RESEARCH AND TREATMENT
- Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
- (2018) Andreas Schneeweiss et al. EUROPEAN JOURNAL OF CANCER
- A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results
- (2018) X. Pivot et al. EUROPEAN JOURNAL OF CANCER
- Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
- (2018) Michail Ignatiadis et al. JNCI-Journal of the National Cancer Institute
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
- (2018) Bernard Asselain et al. LANCET ONCOLOGY
- Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
- (2018) Hikmat Abdel-Razeq et al. OncoTargets and Therapy
- Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
- (2018) Michail Ignatiadis et al. JNCI-Journal of the National Cancer Institute
- The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT)
- (2018) Oluwadamilola M. Fayanju et al. ANNALS OF SURGERY
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status
- (2017) Sylvie Giacchetti et al. EUROPEAN JOURNAL OF CANCER
- Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
- (2017) W. Fraser Symmans et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer
- (2017) Laura Spring et al. Journal of the National Comprehensive Cancer Network
- Pathological responses and long-term outcome analysis after neoadjuvant chemotheraphy in breast cancer patients from Kuwait over a period of 15 years
- (2017) Yamini Krishnan et al. ANNALS OF SAUDI MEDICINE
- Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer.
- (2017) A. Gropper et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy
- (2016) Cynthia Villarreal-Garza et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
- (2016) B. Ingold Heppner et al. CLINICAL CANCER RESEARCH
- Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study
- (2016) Y. Zhang et al. EJSO
- HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up
- (2016) Christian Jackisch et al. EUROPEAN JOURNAL OF CANCER
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
- (2016) Luca Gianni et al. LANCET ONCOLOGY
- Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes
- (2016) Kristine R. Broglio et al. JAMA Oncology
- Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy
- (2016) Sarah S. Mougalian et al. JAMA Oncology
- ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
- (2015) Sasagu Kurozumi et al. BMC CANCER
- Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico
- (2015) Cynthia Villarreal-Garza et al. BREAST
- Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab
- (2015) Arvind M. Shinde et al. BREAST
- Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy
- (2015) Shiwei Liu et al. BREAST CANCER RESEARCH AND TREATMENT
- Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy
- (2015) A M Gonzalez-Angulo et al. BRITISH JOURNAL OF CANCER
- Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
- (2015) Anne-Sophie Hamy-Petit et al. BRITISH JOURNAL OF CANCER
- Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer
- (2015) Erica L. Mayer et al. Clinical Breast Cancer
- High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer to a Novel Nonanthracycline Neoadjuvant Chemotherapy
- (2015) Amelia B. Zelnak et al. Clinical Breast Cancer
- Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype
- (2015) Eun Sook Ko et al. KOREAN JOURNAL OF RADIOLOGY
- High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer
- (2015) T. Kogawa et al. ONCOLOGIST
- Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy
- (2015) Shiwei Liu et al. TUMOR BIOLOGY
- Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study
- (2015) Yi-Zi Zheng et al. Oncotarget
- Neoadjuvant Therapy
- (2015) Howard (Jack) West et al. JAMA Oncology
- Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status
- (2014) Maki Tanioka et al. BREAST
- Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)
- (2014) M. Takada et al. BREAST CANCER RESEARCH AND TREATMENT
- Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data
- (2014) J.-Y. Pierga et al. CLINICAL CANCER RESEARCH
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
- (2014) Evandro de Azambuja et al. LANCET ONCOLOGY
- Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2014) Luca Gianni et al. LANCET ONCOLOGY
- Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer
- (2014) HIDEMI KAWAJIRI et al. Oncology Letters
- Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
- (2013) V. Guarneri et al. ANNALS OF ONCOLOGY
- Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer
- (2013) M. M. Kim et al. ANNALS OF ONCOLOGY
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification
- (2013) S. Saracchini et al. BREAST
- Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients
- (2013) A. Sánchez-Muñoz et al. Clinical & Translational Oncology
- Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer
- (2013) G.C. Zhang et al. Current Oncology
- Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
- (2013) Clara Natoli et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer
- (2013) Jung Hoon Cho et al. JOURNAL OF SURGICAL ONCOLOGY
- Survival Outcomes of Breast Cancer Patients Who Receive Neoadjuvant Chemotherapy: Association with Dynamic Contrast-enhanced MR Imaging with Computer-aided Evaluation
- (2013) Ann Yi et al. RADIOLOGY
- Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice
- (2012) Sonia Pernas et al. BREAST CANCER RESEARCH AND TREATMENT
- Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy
- (2012) Na Rae Ju et al. BREAST CANCER RESEARCH AND TREATMENT
- Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
- (2012) Laura J. Esserman et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis
- (2012) Bohuslav Melichar et al. MEDICAL ONCOLOGY
- Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab
- (2012) Hideyuki Ohzawa et al. Breast Cancer
- Pathologic Response to Short Intensified Taxane-free Neoadjuvant Chemotherapy in Patients with Highly Proliferative Operable Breast Cancer
- (2011) Christophe Le Tourneau et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
- (2011) L. Yao et al. ANNALS OF ONCOLOGY
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
- (2011) Peter A Fasching et al. BMC CANCER
- Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01
- (2011) Seock-Ah Im et al. BREAST CANCER RESEARCH AND TREATMENT
- Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
- (2011) Soley Bayraktar et al. CANCER
- Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
- (2011) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
- (2011) Sylvain Ladoire et al. JOURNAL OF PATHOLOGY
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Long-term Outcome and Pattern of Relapse after Neoadjuvant Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-positive Primary Breast Cancer
- (2009) C. Shimizu et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now